References
- Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. JCO. 2003;21(22):4157–4164.
- Teckie S, Qi S, Lovie S, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 2015;92(1):130–137.
- Jackson AE, Mian M, Kalpadakis C, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, International Experience of 248 Patients (IELSG 41). Oncologist. 2015;20:1149–1153.
- Pinna R, Campus G, Cumbo E, et al. Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Ther Clin Risk Manag. 2015;11:171–188.
- Almstahl A, Skoogh Andersson J, Alstad T, et al. Explorative study on quality of life in relation to salivary secretion rate in head and neck cancer patients treated with radiotherapy up to 2 years post treatment. Int J Dent Hygiene. 2019;17:46–54.
- Gunther JR, Park C, Dabaja BS, et al. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020;61(1):171–175.
- Nelson EC, Eftimovska E, Lind C, et al. Patient reported outcome measures in practice. BMJ. 2015;350(feb10 14):g7818.
- Snyder CF, Jensen RE, Segal JB, et al. Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research. Med Care. 2013;51:S73–S79.
- Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II malt lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;50(5):1258–1264.
- Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington (DC): Institute of Medicine and National Research Council; 2006. Available from: http://www.nap.edu
- Murthy V, Thomas K, Foo K, et al. Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. Clin Lymphoma Myeloma. 2008;8(4):241–245.
- Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–463.
- Brotherston DC, Poon I, Le T, et al. Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck. 2013;35(2):151–159.
- Teckie S, Qi S, Chelius M, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol. 2017;28(5):1064–1069.
- Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.
- Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16(10):1153–1186.
- Blay JY, Coindre JM, Ducimetiere F, et al. The value of research collaborations and consortia in rare cancers. Lancet Oncol. 2016;17(2):e62–e69.
- Mathoulin-Pelissier S, Pritchard-Jones K. Evidence-based data and rare cancers: the need for a new methodological approach in research and investigation. Eur J Surg Oncol. 2019;45:22–30.